Hence, after introducing the importance of the TME in breast cancer and the CCL5/CCR5 axis with its up- and downstream pathways, we highlight the main barriers and hurdles for the clinical adoption of anti-CCR5 therapy in breast cancer. This evidence concerns the gene CCL5 and breast cancer.